Therapeutic trial design for frontotemporal dementia and related disorders

Philippe Desmarais,^{1,2,3,4} Jonathan D Rohrer,⁵ Quoc Dinh Nguyen,⁶ Nathan Herrmann,⁷ Donald T Stuss,^{3,4,8,9} Anthony E Lang,^{4,10} Adam L Boxer,¹¹ Bradford C Dickerson,¹² Howie Rosen,¹¹ John Cornelis van Swieten,¹³ Lieke H Meeter,¹³ Barbara Borroni,¹⁴ Maria Carmela Tartaglia,^{4,10,15} Howard H Feldman,^{16,17} Sandra E Black,^{2,3,4,15} Mario Masellis^{1,2,3,4,15}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2018-318603>).

For numbered affiliations see end of article.

Correspondence to

Dr Mario Masellis, Cognitive & Movement Disorders Clinic, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada; Mario.Masellis@sunnybrook.ca

Received 1 August 2018
Revised 12 September 2018
Accepted 12 September 2018
Published Online First 25 October 2018

ABSTRACT

The frontotemporal dementia (FTD) spectrum is a heterogeneous group of neurodegenerative syndromes with overlapping clinical, molecular and pathological features, all of which challenge the design of clinical trials in these conditions. To date, no pharmacological interventions have been proven effective in significantly modifying the course of these disorders. This study critically reviews the construct and methodology of previously published randomised controlled trials (RCTs) in FTD spectrum disorders in order to identify limitations and potential reasons for negative results. Moreover, recommendations based on the identified gaps are elaborated in order to guide future clinical trial design. A systematic literature review was carried out and presented in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. A total of 23 RCTs in cohorts with diagnoses of behavioural and language variants of FTD, corticobasal syndrome and progressive supranuclear palsy syndrome were identified out of the 943 citations retrieved and were included in the qualitative review. Most studies identified were early-phase clinical trials that were small in size, short in duration and frequently underpowered. Diagnoses of populations enrolled in clinical trials were based on clinical presentation and rarely included precision-medicine tools, such as genetic and molecular testing. Uniformity and standardisation of research outcomes in the FTD spectrum are essential. Several elements should be carefully considered and planned in future clinical trials. We anticipate that precision-medicine approaches will be crucial to adequately address heterogeneity in the FTD spectrum research.

INTRODUCTION

The frontotemporal dementia (FTD) spectrum encompasses a heterogeneous group of neurodegenerative syndromes presenting with a wide range of overlapping clinical features. FTD represents the second most common type of early-onset dementia, approaching the prevalence of Alzheimer's disease (AD) in the 45–64 years age group.^{1,2} It comprises two main clinical phenotypes: behavioural variant FTD (bvFTD), where behavioural changes and executive dysfunction are prominent early manifestations, and primary progressive aphasia (PPA), where comprehension and/or production of language are

impaired.³ PPA is further divided according to the specific language deficits into non-fluent variant PPA (nfvPPA) and semantic variant PPA (svPPA). Another subtype of PPA, logopenic variant PPA, is more frequently associated with underlying Alzheimer's pathology at autopsy.^{4–6} Other FTD spectrum disorders include the clinical phenotypes of progressive supranuclear palsy syndrome and corticobasal syndrome (CBS). Motor manifestations, such as bradykinesia, rigidity and dystonia, and cortical deficits such as apraxia are common manifestations during the course of these disorders.^{7,8} Finally, amyotrophic lateral sclerosis (ALS) is also strongly linked to the FTD spectrum (ie, frontotemporal dementia with motor neuron disease (FTD-MND)) as it shares common pathological findings and genetic mutations.⁹ About 10%–15% of patients with ALS meet the diagnostic criteria for FTD at baseline.¹⁰ While each of these disorders has distinctive features and can be differentiated clinically from one another, there can be overlapping clinical features between the classic clinical phenotypes of FTD spectrum disorders, thus complicating the clinical diagnostic picture.

These neurodegenerative syndromes also share common underlying anatomical, molecular and pathological substrates. Neuropathological examination of individuals with FTD spectrum disorders reveals findings of frontotemporal lobar degeneration (FTLD), where atrophy is prominent in the frontal and/or temporal lobes. In most cases, neuronal loss and gliosis are thought to be secondary to neuronal and astrocytic inclusions of microtubule-associated protein tau, TAR DNA-binding protein 43 (TDP-43), and more rarely RNA-binding protein fused in sarcoma (FUS).^{11–13} Behavioural and language variants of FTD are associated with tau, TDP-43 or FUS proteinopathies,¹⁴ and progressive supranuclear palsy syndrome is most often associated with tau proteinopathy, specifically progressive supranuclear palsy (PSP) pathology.^{7,8} While CBS can also be secondary to tauopathy in the form of corticobasal degeneration (CBD) or PSP, other proteinopathies, such as beta-amyloidopathy/tauopathy (ie, AD), prionopathy, TDP-43 proteinopathy and alpha-synucleinopathy, can also produce the syndrome.^{8,15}

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Desmarais P, Rohrer JD, Nguyen QD, et al. *J Neurol Neurosurg Psychiatry* 2019;**90**:412–423.

Genetic mutations inherited in an autosomal dominant fashion can cause FTD spectrum disorders, with 10%–20% of all cases attributed to mutations in or near three different genes: *C9orf72* (encoding protein C9orf72), *GRN* (encoding progranulin) and *MAPT* (encoding microtubule-associated protein tau).^{11 14 16} Although more rare, other disease-causing genetic mutations have also been identified in heritable FTD, such as in *VCP*, *TARDBP*, *TIA1*, *TBK1* and *CCNF* genes for cases of FTD due to TDP proteinopathy, and in *CHMP2B* and *FUS* for cases of FTD due to tau-negative, TDP-negative, ubiquitin-positive pathology.^{17–19} For PSP and CBD not due to *MAPT* mutations (ie, sporadic disease), common variation in *MAPT*, specifically the *MAPT* H1 haplotype, is an important genetic risk factor for these disorders.²⁰ Variants tagging the *MAPT* H1 haplotype were not surprisingly confirmed in a genome-wide association study (GWAS) of PSP, but several novel common variants in the *STX6*, *EIF2AK3* and *SLC25A38/APPoptosin* genes were found to increase the risk for this disease.^{21 22} With respect to sporadic TDP-43 proteinopathies and those caused by *GRN* mutations, common variants within the *TMEM106B* gene that increase its expression were found to increase the risk and were associated with shorter disease duration in FTD cases; the major allele (T) increased the risk and was associated with a shorter disease duration, while the minor allele (G) had protective effects.²³ In *GRN* carriers, the presence of the *TMEM106B* risk allele was also found to reduce the age of onset by approximately 13 years compared with those without it,²⁴ although this association was not confirmed in a recent GWAS study of *GRN*-related FTD.²⁵ In the latter study, another variant that leads to increased expression of the *GFR2* gene was also found to be associated with increased risk for *GRN*-related FTD.²⁵ The same major allele of *TMEM106B* associated with sporadic and *GRN*-related FTD also conferred an increased risk for *C9orf72*-related FTD and FTD-MND, but not MND.²⁶ Interestingly, the T allele purported to be associated with shorter duration of disease in *GRN*-related FTD was associated with later age of onset and age of death in *C9orf72*-related FTD.²⁷

Despite a better understanding of the pathophysiology and underlying genetic risk factors/modifiers of these disorders, evidence-based pharmacological interventions directed at mitigating their burden on patients are scarce. Currently, no intervention has been shown to alter the evolution of FTD spectrum disorders, and only a handful of small studies have demonstrated symptomatic benefits of pharmacological interventions.²⁸ Designing interventional studies for these disorders is particularly challenging as a result of their low prevalence in the general population, insidious onset, and in many cases aggressive course.^{3 9} Moreover, in the absence of widely accepted sensitive and specific diagnostic biomarkers, the various clinical phenotypes, genetic and pathological heterogeneity, and the overlapping features of these disorders add to the complexity of designing valid clinical trials. Indeed, while the predictive value of established international consensus diagnostic criteria for these disorders continues to improve with every iteration,^{29–32} FTD spectrum disorders are frequently clinically misdiagnosed.³³ Furthermore, with various cognitive, neuropsychiatric and motor manifestations, patients and caregivers' needs are numerous and priorities difficult to establish. Finally, clinical heterogeneity makes it challenging for the development of meaningful clinical outcome measures that are sensitive to change across all of the diverse observed symptoms.

This article has several purposes. First, we present a critical review of the previously published randomised controlled trials (RCTs) of pharmacological interventions for FTD spectrum

disorders wherein we (1) describe the populations studied; (2) examine and analyse the design, methodology and intervention applied in each trial; and (3) synthesise all the various outcomes of interest investigated, as well as the endpoints measured to date. Second, we present recommendations for designing future clinical trials in FTD spectrum disorders based on precision-medicine approaches to address the identified gaps and limitations of previous clinical studies.

METHODS

Study design

A predesigned strategy was used for the literature search, study selection, data extraction and data synthesis. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.³⁴ The protocol was registered prospectively on PROSPERO, where it can be retrieved and reviewed (trial registration number: CRD42018091194).

Search strategy and selection criteria

We performed a systematic review of the literature by using the databases MEDLINE, EMBASE and PsycINFO in order to identify RCTs of pharmacological interventions for the treatment of FTD spectrum disorders, more specifically behavioural and language variants of FTD (bvFTD, svPPA and nfvPPA), PSP syndrome and CBS. Although ALS shares some common molecular and genetic substrates with FTD disorders, and therefore often overlaps clinically with them, we chose to exclude trials on this condition as the design and methodology of ALS trials have already been critically reviewed previously.³⁵ We used keywords including variations on 'frontotemporal dementia' and 'clinical trial' (see full search strategy in online supplementary material 2). We conducted our searches to retrieve articles from inception of databases up to 1 January 2018, without restrictions on language. We manually searched the reference lists of relevant reports for additional citations to supplement our electronic search. Two reviewers (PD and QDN) performed the literature research in parallel and independently. The reviewers met and selected articles to be included in the present study.

Studies were included if they (1) investigated the effects of a pharmacological intervention; (2) were carried out in a population with an FTD spectrum disorder; (3) and were randomised and controlled. Studies were excluded if they (1) were observational/longitudinal studies or (2) represented only post-hoc analysis of previously published trials. Since the main purpose of our review was to identify limitations and gaps in previously published clinical trials, our selection process favoured inclusiveness. When disagreement arose between reviewers on studies to be included in the qualitative review, a third reviewer (MM) resolved the discrepancy.

Data extraction, quality assessment and statistical analysis

Data were abstracted in duplicate, concomitantly and independently by two trained investigators using a standard data abstraction form. Data pertaining to the study's design (eg, condition studied, number of arms, type of intervention, comparator, eligibility criteria, primary and secondary endpoint measurements), the population (eg, size of groups, mean age and SD, percentage of women), the trial's main conclusions, as well as the journal and date of publication were collected. Study quality was assessed with the Cochrane instrument to assess the risk of bias.³⁶ When disagreements arose in coding, resolution was obtained through consensus. We performed descriptive statistics using IBM SPSS Statistics V.24.0.³⁷

Table 1 Randomised controlled trials of pharmacological interventions in FTD spectrum disorders

Study	Condition studied	Cohort size	Trial design	Intervention	Control	Length	Outcome of interest
Leclaire-Visonneau <i>et al</i> ³⁸	PSP syndrome	28	DB, PG, MC	Sodium valproate 1500 mg/day	Placebo	24 months	Symptom progression
Nuebling <i>et al</i> ³⁹	PSP syndrome	44	DB, PG, SC	Rasagiline 1 mg/day	Placebo	12 months	Symptom progression
Apetauerova <i>et al</i> ⁴⁰	PSP syndrome	61	DB, PG, MC	Coenzyme Q10 2400 mg/day	Placebo	12 months	Safety and efficacy on disease progression
Pardini <i>et al</i> ⁴¹	BvFTD	26	SB, CX, SC	Souvenaid 125 mL/day	Placebo	12 weeks	Frontal lobe function
Hughes <i>et al</i> ⁴²	BvFTD	12	DB, CX, SC	Citalopram Single-dose 30 mg	Placebo	2 sessions*	Frontal lobe function
Finger <i>et al</i> ⁴³	BvFTD and SD	23	DB, PG, SC	Oxytocin 24, 48, 72 IU Twice daily	Placebo	1 week	Safety and tolerability, symptom progression
Tolosa <i>et al</i> ⁴⁴	PSP syndrome	146	DB, PG, MC	Tideglusib 600 or 800 mg/day	Placebo	52 weeks	Safety and disease progression
Höglinger <i>et al</i> ^{45†}	PSP syndrome	37	DB, PG, MC	Tideglusib 600 or 800 mg/day	Placebo	52 weeks	Disease progression on brain imaging
Boxer <i>et al</i> ⁴⁶	PSP syndrome	313	DB, PG, MC	Davunetide 30 mg twice daily	Placebo	52 weeks	Safety and efficacy on disease progression
Boxer <i>et al</i> ⁴⁷	BvFTD and SD	81	DB, PG, MC	Memantine 10 mg twice daily	Placebo	26 weeks	Symptom progression
Jesso <i>et al</i> ⁴⁸	BvFTD	20	DB, CX, SC	Oxytocin Single-dose 24 IU	Placebo	1 week	Emotion recognition
Vercelletto <i>et al</i> ⁴⁹	BvFTD	52	DB, PG, MC	Memantine 10 mg twice daily	Placebo	52 weeks	Symptom progression
Bensimon <i>et al</i> ⁵⁰	PSP syndrome and MSA	767 (363 with PSP)	DB, PG, MC	Riluzole 50–200 mg/day	Placebo	35 months	Survival and disease progression
Stamelou <i>et al</i> ⁵¹	PSP syndrome	21	DB, PG, SC	Coenzyme Q10 5 mg/kg/day	Placebo	6 weeks	Symptom progression and energy metabolite on MRS
Kertesz <i>et al</i> ⁵²	BvFTD and PPA	36	OL and DB, PG, SC	Galantamine 16–24 mg/day	Placebo	OL: 18 weeks DB: 8 weeks	Symptom progression
Rahman <i>et al</i> ⁵³	BvFTD	8	DB, CX, SC	Methylphenidate Single-dose 40 mg	Placebo	2 sessions*	Frontal lobe function
Deakin <i>et al</i> ⁵⁴	BvFTD	10	DB, CX, SC	Paroxetine 40 mg/day	Placebo	7 weeks	Frontal lobe function
Moretti <i>et al</i> ⁵⁵	FTD	40	OL, PG, SC	Rivastigmine 3–9 mg/day	Standard treatment	12 months	Symptom progression
Lebert <i>et al</i> ⁵⁶	BvFTD	31	DB, CX, MC	Trazodone 300 mg/day	Placebo	6 weeks	Symptom progression
Moretti <i>et al</i> ⁵⁷	FTD	16	OL, PG, SC	Paroxetine 20 mg/day	Piracetam 1200 mg/day	14 months	Symptom progression
Litvan <i>et al</i> ⁵⁸	PSP syndrome	21	DB, CX, SC	Donepezil 10 mg/day	Placebo	6 weeks	Symptom progression
Frattali <i>et al</i> ⁵⁹	PSP syndrome	6	DB, CX, SC	Physostigmine 0.5–2 mg Every 2 hours	Placebo	3–4 days	Oral motor functions
Rascol <i>et al</i> ⁶⁰	PSP syndrome	14	DB, CX, MC	Efaroxan 2 mg Three times a day	Placebo	6 weeks	Motor symptom progression

*Studies involved administration of a single dose of the investigational drug or placebo followed by same-day cognitive assessment.

†This was a substudy of the above study.

BvFTD, behavioural variant frontotemporal dementia; CX, crossover; DB, double-blind; FTD, frontotemporal dementia; MC, multicentre; MRS, magnetic resonance spectroscopy; MSA, multisystem atrophy; OL, open-label; PG, parallel-group; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy; SB, single-blind; SC, single-centre; SD, semantic dementia.

RESULTS

Search results and study characteristics

A total of 947 abstracts were identified, of which 75 citations were reviewed at the full-text stage (see online supplementary figure S1 for the PRISMA flow chart). Of the articles reviewed in their entirety, 52 did not meet the inclusion criteria and were excluded. The 23 remaining articles were included in the present

qualitative synthesis (table 1).^{38–60} Risk of bias in the included studies was perceived as low (see online supplementary data). From 1998 to 2016, a total of 1362 participants (44% female) with an FTD spectrum disorder were randomised to clinical trials. BvFTD and PSP syndrome were the most studied clinical conditions with 12 trials (52%) and 11 trials (48%) published, respectively. Three trials (13%) included participants with different

subtypes of PPA. No interventional trial involving participants with CBS was identified. Of note, a large unpublished clinical trial of leuco-methylthionium was also identified and involved 220 participants with a diagnosis of bvFTD. [S61] The largest trial in size for PSP syndrome also included participants with multiple system atrophy (MSA), with 363 participants with PSP syndrome (47%) and 404 with MSA (53%).⁵⁰ Most trials were small in size, with only three trials (13%) having randomised more than 100 participants.

Several different drugs and regimens have been investigated as potential symptomatic therapies, with acetylcholinesterase inhibitors (donepezil, galantamine and rivastigmine) being the most frequently investigated drugs, followed by antidepressants (citalopram and paroxetine) and oxytocin, a neuropeptide (see online supplementary table S1). Investigations for potential disease-modifying agents were mainly performed in PSP syndrome and included coenzyme Q10,^{40 51} davunetide,⁴⁶ rasagiline,³⁹ riluzole,⁵⁰ sodium valproate³⁸ and tideglusib.^{44 45} A cross-over design was used in nine trials (39%), specifically for six symptomatic drug trials and three disease-modifying drug trials. The duration of interventions was shorter than 3 months for more than half of the trials (52%).

Eligibility criteria in clinical trials

A summary of the main eligibility criteria for enrolment in these clinical trials is provided in table 2. For studies carried out in bvFTD, seven trials (58%) reported age requirements for inclusion, with a minimum age for inclusion ranging from 30 to 60, and the maximum age for inclusion ranging from 65 to 80. Eight trials (67%) explicitly excluded participants with advanced disease, defined by the presence of significant cognitive impairment. However, only four trials reported a specific threshold score for exclusion, which was based on the Mini-Mental State Examination (MMSE). Confirmatory abnormality on brain imaging, mainly frontotemporal atrophy, was the only biomarker requirement retrieved in the included clinical trials and was explicitly required for enrolment in seven of the bvFTD trials (58%). The scales used to assess severity of brain atrophy on imaging were not explicitly reported in the published articles, while the unpublished clinical trial in bvFTD [S61] enrolled participants with evidence of frontal and/or temporal lobe atrophy on MRI at Kipps level 2 or greater. [S62] None of the trials in bvFTD reported subsequent pathological confirmation following clinical diagnosis.

For studies carried out in PPA, all three trials (100%) reported the use of age requirements, all excluding participants aged 80 years and older. Participants with advanced disease, defined by significant cognitive impairment on cognitive screening tests, were also excluded from these trials, with two trials (66%) reporting a specific MMSE threshold score for exclusion. The clinical diagnosis of enrolled PPA cases was supported by the presence of neuroimaging abnormalities, such as frontotemporal atrophy or hypoperfusion. The scales used to assess brain atrophy or hypoperfusion on imaging were not explicitly reported. None of the trials reported subsequent pathological confirmation following clinical diagnosis.

For studies conducted in PSP syndrome, all trials except one explicitly reported the use of age requirements for inclusion of participants. Six trials (55%) excluded participants with significant cognitive impairment, with four trials (36%) using a specific MMSE threshold score. Only two trials (18%) explicitly reported the use of neuroimaging for corroboration of clinical diagnosis. Finally, two trials (18%) mentioned subsequent

pathological confirmation of the clinical diagnosis for a portion of the included participants.

Outcomes of interest and endpoint measures in clinical trials

Several different main outcomes of interest related to cognitive, language, neuropsychiatric and motor manifestations have been investigated in these clinical trials (table 1). Similarly, the effects of investigational drugs on the progression of symptoms were assessed through the use of various different scales and tools. The various scales and tools that have been used in these studies are reported in online supplementary table S2.

All clinical trials in bvFTD but one focused on the treatment of neuropsychiatric symptoms, with the Neuropsychiatric Inventory [S63] and Frontal Behavioural Inventory [S64] being the most commonly used tools. The other trial⁵³ investigated specifically the effect of methylphenidate on decision-making behaviour. Several scales and tools in regard to social cognition have also been used, including the Reading the Mind in the Eye Test, [S65] the Interpersonal Reactivity Index, [S66] and the Facial Expression Recognition Task. [S67] There were a variety of outcomes in clinical trials in PPA, including management of neuropsychiatric symptoms and palliation of language difficulties. All clinical trials in PSP syndrome except one explored the effects of investigational drugs on motor symptoms with the use of motor scales, with the Progressive Supranuclear Palsy Rating Scale (PSPRS) and the Unified Parkinson's Disease Rating Scale being the most commonly used tools. One trial⁵⁹ investigated specifically the effect of physostigmine on swallowing abilities. In regard to patient-centred outcomes, three trials (25%) in bvFTD and two trials (66%) in PPA reported measurements related to these, including tolerability of drug and impact on functional independency. In PSP syndrome, nine trials (82%) reported patient-centred outcomes, such as quality of life, autonomy and tolerability of treatment. Finally, only three trials (13%), all conducted in bvFTD, reported caregiver-related outcomes, such as caregiver burden.

DISCUSSION

Heterogeneity in clinical trials

This systematic review of RCTs of pharmacological therapies for FTD spectrum disorders, with a focus on methodology, highlights some of the current challenges in designing and conducting clinical trials in these conditions. The significant heterogeneity in design and methodology of the identified clinical trials reflects the complexity of these syndromes and their underlying pathologies. Participants with different clinical phenotypes have been enrolled in these studies using diverse eligibility criteria based on the clinical diagnosis, age at baseline, as well as the presence or absence of certain cognitive deficits. Numerous drugs with different pharmacodynamic and pharmacokinetic properties have been investigated as potential disease-modifying interventions or symptomatic treatments of diverse symptoms and deficits (online supplementary table S1). Similarly, numerous tools and scales with different psychometric properties have been used to measure the effects of these investigational drugs (online supplementary table S2).

Limitations and challenges

Several limitations have been identified in these clinical trials, some of which could explain their negative results. First, clinical diagnosis for enrolment was not always detailed or clearly reported in the studies. This could be partly explained by the fact that the terminology has significantly evolved over the past

Table 2 Eligibility and clinical diagnostic criteria of FTD spectrum disorders used in randomised controlled trials

Study	Clinical diagnostic criteria used	Age for inclusion	Cognitive impairment exclusion	Biomarkers used for inclusion*	Pathology confirmation
Behavioural variant FTD					
Pardini <i>et al</i> ⁴¹	Rascovsky 2011 ³⁰	50–65	NS	None	No
Hughes <i>et al</i> ⁴²	Probable bvFTD Rascovsky 2011 ³⁰	NS	NS	Abnormal brain imaging	No
Finger <i>et al</i> ⁴³	Probable bvFTD Rascovsky 2011 ³⁰	30–80	'Disease severity too advanced to participate'	Neuroimaging supports diagnosis (CT, MRI or SPECT)	No
Boxer <i>et al</i> ⁴⁷	Nearby 1998	40–80	MMSE <15	Characteristic brain atrophy	No
Jesso <i>et al</i> ⁴⁸	Nearby 1998	NS	'Comprehension deficits or language impairment'	MRI, CT or SPECT imaging consistent with diagnosis	No
Vercelletto <i>et al</i> ⁴⁹	Nearby 1998	45–75	MMSE <19	None	No
Kertesz <i>et al</i> ⁵²	Nearby 1998	30–80	MMSE ≤5	Frontotemporal lobar atrophy on imaging	No
Rahman <i>et al</i> ⁵³	The Lund and Manchester Groups 1994	NS	MMSE ≤20	None	No
Deakin <i>et al</i> ⁵⁴	Nearby 1998	NS	NS	None	No
Moretti <i>et al</i> ⁵⁵	The Lund and Manchester Groups 1994	60–75	'Significant impairment'	Frontal cortex atrophy on imaging	No
Lebert <i>et al</i> ⁵⁶	The Lund and Manchester Groups 1994	NS	NS	None	No
Moretti <i>et al</i> ⁵⁷	The Lund and Manchester Groups 1994	60–70	'Significant impairment'	Frontal cortex atrophy on imaging	No
Primary progressive aphasia					
Finger <i>et al</i> ⁴³	Semantic aphasia (with behavioural features) Nearby 1998	30–80	'Disease severity too advanced to participate'	Neuroimaging supports diagnosis (CT, MRI or SPECT)	No
Boxer <i>et al</i> ⁴⁷	Semantic aphasia Nearby 1998	40–80	MMSE <15	Characteristic brain atrophy	No
Kertesz <i>et al</i> ⁵²	Mesulam 1987	30–80	MMSE ≤5	Frontotemporal lobar atrophy on imaging	No
Progressive supranuclear palsy syndrome					
Leclair-Visonneau <i>et al</i> ³⁸	Possible or probable PSP Litvan 1996	45–75	MMSE ≤22	None	No
Nuebling <i>et al</i> ³⁹	Probable PSP Litvan 1996	50–80	MMSE ≤24	None	No
Apetauerova <i>et al</i> ⁴⁰	Probable PSP Litvan 1996	≥40	NS	None	No
Tolosa <i>et al</i> ⁴⁴	Possible or probable PSP Litvan 1996	40–85	NS	MRI consistent with PSP and ruling out relevant vascular pathology	No
Höglinger <i>et al</i> ⁴⁵	Possible or probable PSP Litvan 1996	40–85	NS	MRI consistent with PSP and ruling out relevant vascular pathology	No
Boxer <i>et al</i> ⁴⁶	Probable or possible PSP NNIPPS 2009	41–85	MMSE <15	None	No
Bensimon <i>et al</i> ⁵⁰	Simplified operational diagnostic criteria (NNIPPS) from consensus criteria (Litvan 1996 and 2003)	≥30	NS	None	Histopathological analysis of 112 of 767 cases: 94% correct
Stamelou <i>et al</i> ⁵¹	Probable PSP Litvan 1996	≤85	MMSE ≤24	None	No
Litvan <i>et al</i> ⁵⁸	Possible or probable PSP Litvan 1996	NS	'Absence of frontal, behavioural or cognitive dysfunction'	None	Histopathological analysis of 4 of 21 cases: 100% correct
Frattali <i>et al</i> ⁵⁹	Based on Litvan 1996	≥50	NS	None	No
Rascol <i>et al</i> ⁶⁰	Lees 1987	40–80	'Not severely demented according to DSM-IV criteria'	None	No

*Possible biomarkers such as findings on structural or functional brain imaging, cerebrospinal fluid or genetic mutations.

DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; FTD, frontotemporal dementia; MMSE, mini- mental state examination; NNIPPS, neuroprotection and natural history in Parkinson plus syndromes; NS, not specified; PSP, progressive supranuclear palsy; SPECT, single-photon emission CT; bvFTD, behavioural variant FTD.

decade as our understanding and conceptualisation of these disorders have improved. As well, inclusion of participants with concomitant MND was only reported explicitly in one study.⁴⁷ Second, the use of biomarkers for corroboration of clinical

diagnosis, or for exclusion of other neurocognitive disorders, was limited to the presence or absence of typical brain imaging abnormalities, mainly cerebral atrophy on CT scans and/or MRI, hypometabolism on FDG-positron-emission tomography (PET)

scans, or hypoperfusion on single-photon emission CT scans in frontotemporal regions. With the notable exception of the Kipps scale used in one study [S61], the specific tools to assess brain imaging abnormalities were rarely reported in the retrieved studies. None of the trials explicitly reported the use of, for instance, cerebrospinal fluid analysis (CSF) or genetic testing for assessing the eligibility of participants. However, it must be stated that most of these clinical trials predated the discovery of genetic and other potential biomarkers.

Current international consensus clinical diagnostic criteria have limitations, as demonstrated in studies on neurocognitive disorders such as AD, Parkinson's disease dementia and bvFTD. [S68–S71] Clinical diagnoses do not always match the final pathology results, with reported inaccurate diagnosis of AD pathology ranging from 19% to 45% in one cohort study. [S68] While recent iterations of clinical diagnostic criteria for FTD spectrum disorders have increased their sensitivities, such as Rascovsky's criteria improving from previous diagnostic criteria of bvFTD (86% compared with 53% sensitivity),³⁰ current criteria tend to have higher specificities than sensitivities.^{29–32} Thus, patients with some classical features of FTD may not meet the full criteria for diagnosis [S72] or can meet more than one criterion across different syndromes. [S71] Furthermore, multiple comorbid neurodegenerative and non-neurodegenerative findings may be present at autopsy. [S73–S77] For instance, α -synucleinopathies (24.9%), tauopathies (23.2%), TDP-43 proteinopathy (13.3%) and vascular lesions (48.9%) were identified in the brains of elderly individuals with and without dementia in a large community-based autopsy series. [S73] Hence, definitions of neurodegenerative disorders based exclusively on clinical signs and symptoms may not fully grasp the heterogeneity of underlying pathologies. Third, clinical trials in bvFTD where brain atrophy on imaging was not required for participants' eligibility may have unintentionally randomised phenocopy cases. These slowly progressive and sometimes non-progressive cases, which fulfil the neuropsychological and neuropsychiatric criteria for bvFTD, appear to be neuropathologically distinct from other forms of FTD at autopsy, with the notable exception of *C9orf72* mutation cases. [S78] Previously enrolled participants of RCTs may not have had the expected underlying pathology; thus, the drug being tested might have been off target. Fourth, most of the retrieved studies were early-phase clinical trials aimed at assessing safety and tolerability, hence their short durations and small cohort sizes. These could preclude the detection of a treatment effect especially relating to disease modification, which would need potentially a longer observation period. With the exception of a few multicentre trials that were able to recruit larger cohorts, most clinical trials identified were small in size and may have lacked statistical power. Single-centre trials often had a cross-over design, while multicentre trials had a classic placebo-controlled, parallel-group design. Fifth, previous RCTs of pharmacological interventions may have been attempted too late in the course of the disease, potentially missing the therapeutic window of opportunity. Finally, selected tools and clinical scales used to measure treatment effect may not have been sensitive enough to capture significant changes in symptoms or disease progression as they may not cover effectively all of the various clinical manifestations of the FTD spectrum or fail to take into account the functional-anatomical specificity of the frontal regions.

Addressing limitations and moving forward

In the context of complex clinical manifestations and pathological heterogeneity, uniformity and standardisation in future

clinical trials for FTD spectrum disorders are needed. Precision-medicine approaches, where interventions are designed by considering the patient's specific clinical syndrome as well as disease profile in regard to its underlying molecular and genetic signatures, offer opportunities to address some of the current challenges. The following elaborated recommendations for future clinical trials in the FTD spectrum disorders should be considered (see table 3).

The diagnoses of participants enrolled in clinical trials and their supportive findings should be clearly defined and reported. Initial clinical diagnoses should be prospectively reassessed as participants' clinical presentation may change over time. [S71, S79–S81] Additionally, subsequent pathological confirmation of participants' diagnoses should be attempted whenever possible. This could be facilitated by systematically discussing brain donation with every eligible participant before enrolment in a clinical trial. FTD spectrum disorders have a wide range of clinical manifestations, which frequently overlap with each other.^{3 33} Therefore, investigations allowing exclusion of other disorders that may mimic FTD spectrum disorders, such as other neurodegenerative disorders (eg, AD), psychiatric disorders and vascular disease, should be rigorously performed. [^{8 14 33} S75, S76] As well, phenocopies of bvFTD should also be identified as they can also contribute to pathological misclassification in clinical trials. [S82] Although it may be difficult to accomplish this before randomisation, clinical suspicion should increase in the context of participants with non-progressive conditions. FTD spectrum disorders are biologically heterogeneous, involving several different pathological inclusion proteinopathies, variants and subtypes, and cerebral topographies, which should all be considered in clinical trials.^{11 14} [S83–S87] Although there are still no widely accepted biomarkers that are both sensitive and specific, some molecular and genetic findings could potentially be used as eligibility criteria for clinical trials in FTD spectrum disorders. Possible examples include plasma progranulin levels, where decreased levels can predict the presence of *GRN* mutations, [S88–S92] and plasma and CSF neurofilament light chain protein levels, where levels could reflect disease severity. [S93–S96] In the (hopefully) near future, a tau-ligand PET scan could help increase accuracy of clinical diagnoses, where FTL cases due to TDP-43 proteinopathy would be PET-negative and cases due to tauopathy would be PET-positive. [S97–S100] Considering the important contribution of genetic mutations and variants to these disorders, genetic testing should be an integral part of the selection process of participants. [S101–S104] A known genetic profile is informative of the expected natural progression of the underlying disorder. For instance, *C9orf72* promoter hypermethylation is associated with prolonged disease duration in expansion carriers. [S105–S106] Although uncommon, the possibility of co-occurrence of genetic mutations should also be considered, such as *C9orf72* repeat expansion carriers also harbouring *GRN* or *MAPT* gene mutations. [S107] Moreover, molecular and genetic factors could potentially represent interesting targets for future drugs, such as the open-label trial of nimodipine in progranulin deficiency, [S108] as well as markers of pharmacological response or adverse effects, similar to previously identified genetic drug response markers in Parkinson's disease. [S109] With improvement of target engagement, specifying whether the diagnosis of a participant is based solely on clinical signs or in conjunction with molecular, genetic or histopathological findings is essential as these markers significantly improve the prediction of the correct underlying pathological process and hence the presence of the pharmacological target (see figure 1).

Table 3 Recommendations for future clinical trials in FTD spectrum disorders

Element	Recommendations and <i>examples</i>
Diagnosis	<p>Investigators should clearly state if participants enrolled in the clinical trial have:</p> <ul style="list-style-type: none"> ► Clinical diagnosis according to current international consensus diagnostic criteria, such as: <ul style="list-style-type: none"> – Probable bvFTD according to Rascovsky 2011³⁰ criteria. ► Molecular findings supportive of FTLT or absence of biomarkers suggestive of another diagnosis, such as: <ul style="list-style-type: none"> – Hypometabolism on PET scan suggestive of FTD. – Cerebral atrophy in frontotemporal regions suggestive of FTD. – Negative amyloid PET imaging. ► Genetic diagnosis according to the presence of a known disease-causing mutation, such as: <ul style="list-style-type: none"> – Common gene mutations: <i>C9orf72</i>, <i>GRN</i> and <i>MAPT</i>. – Rare gene mutations: <i>VCP</i>, <i>TARDBP</i>, <i>TIA1</i>, <i>TBK1</i>, <i>CCNF</i>, <i>FUS</i> and <i>CHMP2B</i>. ► Histopathological diagnosis, such as: <ul style="list-style-type: none"> – Subsequent autopsy confirmation of clinical diagnosis. <p>If participants have a molecular, genetic or histopathological diagnosis, it should be stated if participants are asymptomatic/presymptomatic or symptomatic.</p> <p>The natural disease progression of enrolled participants should be carefully examined to determine whether it is slowly or rapidly progressing.</p> <p>The presence of concomitant motor neuron disease should be reported.</p>
Study design	<p>Innovative study design and methodology should be considered in order to maximise chance of capturing positive effects.</p> <ul style="list-style-type: none"> ► International multicentre trials should be prioritised, such as: <ul style="list-style-type: none"> – The GENFI cohort. – The LEFFTDS cohort. – The ARTFL cohort. ► Platform trials, multi-interventional, multiarm trials should be considered, such as: <ul style="list-style-type: none"> – Multiple molecular targets. – Combination therapies. – Non-pharmacological intervention with pharmacological intervention. ► Collaboration between the pharmaceutical industry, clinicians, clinical trial statisticians, statistical geneticists and bioinformaticians should be promoted. ► Interventional trials in presymptomatic high-risk participants should be attempted. ► Prespecified post-hoc analyses should be considered to find subgroup responders. <p>Interventions should be clearly defined as to whether they are preventive, disease-modifying and/or symptomatic in nature.</p>
Eligibility criteria	<p>Inclusion and exclusion criteria should be clearly reported and justified. The following variables should be carefully addressed:</p> <ul style="list-style-type: none"> ► Minimum and maximum age limits should be justified. ► Adequate sex representation should be sought by avoiding exclusion criteria that preferentially affect one sex over the other. ► Significant cognitive impairment precluding randomisation should be carefully defined and justified. ► Non-FTD cases should be excluded through the use of biomarkers such as CSF amyloid beta or amyloid PET imaging.
Outcome of interest	<p>Investigators should clearly state outcomes of interest of the study and whether they pertain to:</p> <ul style="list-style-type: none"> ► Patient-centred and/or caregiver-centred outcomes, such as: <ul style="list-style-type: none"> – Quality of life. – Caregiver burden. – Autonomy/independency. – Risk of institutionalisation. ► Surrogate outcomes, such as: <ul style="list-style-type: none"> – Brain atrophy on imaging. – Tau brain deposits on imaging. – Progranulin plasma level. ► Symptomatology: ► Cognitive outcomes, such as: <ul style="list-style-type: none"> – Frontal lobe functions. – Language. ► Neuropsychiatric outcomes, such as: <ul style="list-style-type: none"> – Apathy and disinhibition. – Depression. ► Motor outcomes, such as: <ul style="list-style-type: none"> – Speech. – Mobility. – Dystonia. <p>Patients, families and caregivers should be involved in the decision process of selecting and prioritising future clinical trials' main goals.</p>
Endpoint measure and effect assessment	<p>Several accurate and validated tools and scales should be used, in combination with more commonly used clinical scales, in order to encompass disease heterogeneity, including global and specific scales:</p> <ul style="list-style-type: none"> ► Disease-specific scales, such as: <ul style="list-style-type: none"> – CDR-FTLD. – PSPRS. ► Severity of symptoms and deficits: ► Cognitive scales. <ul style="list-style-type: none"> – General cognitive scales, such as DRS and MoCA. – Specific cognitive domain tools, such as: <ul style="list-style-type: none"> – Processing speed: Simple Reaction Time, Choice Reaction Time. – Attention and working memory: Forward Digit Span, Backward Digit Span. – Executive functioning: Stroop Task, Trail-Making Test, Verbal Fluency. – Language: Boston Naming Test, Western Aphasia Battery. – Social cognition: ToM tasks, Interpersonal Reactivity Index.

Continued

Table 3 Continued

Element	Recommendations and examples
	<ul style="list-style-type: none">▶ Neuropsychiatric scales, such as:<ul style="list-style-type: none">– FBI.– NPI.▶ Motor measures, such as:<ul style="list-style-type: none">– Time to being a wheelchair user.– Time to unintelligible speech.– UPDRS score. <p>Multidimensional patient and caregiver-reported measures should be included in the treatment effect assessment, including functional and quality of life scales.</p> <p>Potential differential effect of the investigational drug should be sought in subgroup analysis or by including the following variables as covariates of interest:</p> <ul style="list-style-type: none">▶ Age.▶ Sex.▶ Genetic variants, such as:<ul style="list-style-type: none">– <i>MAPT</i> H1 haplotype.– <i>TMEM106B</i> genotype.▶ Copathology.

Italicized items in the table represent examples.

ARTFL, Advancing Research and Treatment for Frontotemporal Lobar Degeneration; BvFTD, behavioural variant FTD; CDR-FTLD, Clinical Dementia Rating Scale-Frontotemporal Lobar Degeneration; CSF, cerebrospinal fluid; DRS, Dementia Rating Scale; FBI, Frontal Behavioural Inventory; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; GENFI, Genetic Frontotemporal Dementia Initiative; LEFFTDS, Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects; MoCA, Montreal Cognitive Assessment; NNIPPS, Neuroprotection and Natural History in Parkinson Plus Syndromes; NPI, Neuropsychiatric Inventory; PET, positron-emission tomography; PSPRS, Progressive Supranuclear Palsy Rating Scale; ToM, theory of mind; UPDRS, Unified Parkinson's Disease Rating Scale.

Different clinical trials should involve participants at diverse stages of the disease, including presymptomatic stages. Similar to AD, FTD spectrum disorders progress over years before clinical manifestations and brain changes such as hypometabolism, hypoperfusion and atrophy become apparent (see figure 2). [S110, S111] Although penetrance of known mutations may

vary considerably according to several factors (eg, *TMEM106B* genotype), future clinical trials should investigate potential disease-modifying interventions in high-risk asymptomatic individuals, who are mutation carriers. Identifying and recruiting presymptomatic individuals in studies may be difficult but is feasible, as demonstrated by the Genetic Frontotemporal

Figure 1 Selection process of participants for FTD spectrum disorders clinical trials based on precision-medicine approaches. A graphical representation of the proposed selection and triage process of potential eligible participants for future clinical trials in FTD spectrum disorders based on precision-medicine approaches. First, subjects are assessed clinically to determine the presence of a clinical syndrome according to the international consensus diagnostic criteria (eg, bvFTD). Then, symptomatic and asymptomatic subjects undergo genetic testing to identify mutation carriers (eg, *C9orf72*, *GRN*, *MAPT*, *VCP* and *TARDP*), as well as genetic variants (eg, *APOE* epsilon 4 allele, *HLA*, *MAPT* H1 haplotype and *TMEM106B* T allele) that may modify age of onset or increase the risk of a specific pathological substrate. In the circumstance that potential eligible participants would not want to be informed of their mutation status, they could still be able to enrol in clinical trials. Finally, subjects undergo further testing to identify the presence of FTLD-specific biomarkers and molecular targets (eg, progranulin plasma level and CSF tau level). This selection process permits the exclusion of subjects with a low risk of developing FTLD and those with non-FTLD pathology, such as Alzheimer's disease. Clinical trials can then be conducted in a population with a well-characterised disease where the investigational drug's target is present. bvFTD, behavioural variant FTD; CSF, cerebrospinal fluid; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; PET, positron-emission tomography.

Neurodegeneration

Figure 2 Windows of opportunities for pharmacological interventions in FTD spectrum disorders according to disease progression. A graphical representation of the theoretical progression of FTD spectrum disorders over time and potential windows of opportunity for pharmacological interventions. CSF, cerebrospinal fluid; FTD, frontotemporal dementia; FTLD, frontotemporal lobar degeneration; TDP-43, TAR DNA-binding protein 43.

Dementia Initiative (GENFI), [S111] the Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS), [S112] and the Advancing Research and Treatment for FTLD (ARTFL) studies. [S113]

Since FTD spectrum disorders have a low prevalence and incidence in the general population compared with AD,^{1,2} innovative methodologies and study designs should be sought. Statistically meaningful results require enrolment of a sufficient number of participants. Therefore, international initiatives and collaborations, such as the Neuroprotection and Natural History in Parkinson Plus Syndromes Study⁵⁰ and ‘clinical trial ready’ cohorts such as GENFI, [S111] LEFFTDS, [S112] and ARTFL [S113] are essential to test new clinical questions and to establish biomarkers that can be used as outcome measures. Initiating, implementing and maintaining international networks come with challenges and obstacles, such as additional financial costs, cultural and language differences, and data transmission issues, just to name a few. But these collaborations are highly valuable in the long run. The Dominantly Inherited Alzheimer Network-Trials Unit represents an example of a successful international clinical trial in autosomal dominant AD. [S114] International research registries and networks facilitate recruitment of potential research participants and promote alliances between healthcare providers and researchers.

Conducting adaptive clinical trials with Bayesian models and platform trials, such as the Glioblastoma Adaptive Global Innovative Learning Environment, [S115] are interesting avenues to investigate multiple prospective pharmacological interventions aimed at specific target points in a short amount of time. [S116,S117] Furthermore, in the absence of effective treatments, pharmacological and non-pharmacological interventions, such as exercise, should be coinvestigated in parallel

and in combination in order to maximise chances of identifying interventions with symptomatic benefits. Successful drug-tailoring for rare diseases is possible, such as it was recently done in spinal muscular atrophy with the development of nusinersen, an antisense oligonucleotide drug. [S118,S119] Similar to therapies in oncology and microbiology, administration of several drugs with different pharmacodynamic properties in combination may be necessary in order to have a disease-modifying effect in FTD spectrum disorders.

Exclusion criteria should be carefully planned so as not to exclude certain subgroups of individuals. Historically, women [S120,S121] and the elderly [S122–S125] have been under-represented in clinical trials. There is evidence of sex differences in the clinical manifestations of genetic mutations in FTD, which could translate into differential treatment effects. [S126] Specifically, there appears to be a higher prevalence of female patients with *GRN*-related FTD [S126], indicating that future clinical trials in *GRN*-related FTD should adjust for potential sex effects. Although exclusion of participants with advanced age can be justified by the increased prevalence of comorbid cerebral pathology, [S73,S76,S127–S129] the higher risk of adverse effects of investigational drugs, [S130,S131] and different progression rates of diseases, [S132,S133] differential treatment effects should be explored by subgroup analyses. Older age at onset may also increase the likelihood of an FTD case being sporadic where underlying pathologies and risk factors are different from those in early-onset cases, which may be more likely to have an identifiable genetic mutation. Similarly, exclusion of participants with cognitive impairment should be clearly justified. Cognitive deficits are nearly universal during the course of FTD spectrum disorders, and the ideal screening tool and threshold score for inclusion/

exclusion remain to be determined. The MMSE is not the most sensitive nor specific screening tool for the assessment of cognitive deficits in these disorders. [S134,S135] As well, the MMSE may not be discriminative enough to help in determining the stage of these disorders early in their course. For instance, language impairment affects the assessment of other cognitive domains, and the use of a specific threshold score for inclusion may inappropriately exclude participants with aphasia from clinical trials, despite them having little or no other important cognitive or behavioural impairment. [S135]

Researchers should prioritise the investigation of pharmacological interventions aimed at patient-centred and caregiver-centred outcomes. There is currently an unmet need for effective symptomatic therapies at all stages of these disorders. Patients, families and caregivers should be involved as research partners in the decision process in order to identify and prioritise goals to pursue in future clinical trials. The Association for Frontotemporal Degeneration, the FTD Disorders Registry and the FTD Treatment Study Group are all encouraging these and other partnerships. As well, studies should clearly define and report whether the outcomes of interest of the investigated treatment relate to prevention, symptomatic relief and/or disease modification. Clinical trials with longer observation periods should be undertaken in order to capture disease-modifying effects of investigational drugs.

FTD spectrum disorders have various cognitive, neuropsychiatric and motor manifestations, which may require different pharmacological interventions to treat them, and consequently necessitate different assessment tools and scales to measure the effects of the interventions. Tools specifically designed for FTD spectrum disorders, which take into consideration the various manifestations of these disorders (ie, global composite measures), should be prioritised, such as the Clinical Dementia Rating Scale-FTLD [S136–S138] and the PSPRS. [S139,S140] Tools assessing disease severity in specific domains, such as frontal system functions, should be used in conjunction. [S141] As well, it should be acknowledged that some clinical manifestations may interfere with the assessment of several other cognitive, neuropsychiatric and motor impairments, affecting interpretation of results. Functional scales taking this fact into consideration should also be prioritised, such as the CBD-Functional Rating Scale. [S142] Multidimensional patient-reported and caregiver-reported measures should likewise be integrated in future clinical trials. An interesting avenue includes the Goal Attainment Scaling instrument, which is a personalised outcome measure where patients and caregivers set the treatment goals. [S143] Another alternative approach to identifying a treatment effect is to capture change in symptoms and functions using a variety of different rating instruments previously used, but then to identify a composite clinical effect through the use of eigenfunctions and multifactor dimensionality reduction approaches applied to the comprehensive data set collected. In addition, change in neuroimaging measures over time, especially in the case of presymptomatic prevention trials, should also be explored as a potential outcome measure to consider in conjunction with clinical measures. These include reduction in the rate of atrophy on MRI and reduction in tau burden on PET (once a viable tracer has been validated). Furthermore, increases in plasma and/or CSF progranulin levels for *GRN*-related FTD may also be a possible treatment goal, although there has not been a good correlation observed between disease measures and progranulin levels to date. In addition, the arrival of new technologies to assist with the assessment and monitoring

of individuals with cognitive and functional deficits, such as wearable devices, is an exciting moment in dementia research and could offer novel ways to capture the effects of clinical interventions in the near future.

Finally, with our increased understanding of rare, causative mutations for genetic FTD and common genetic variation that increases risk for sporadic FTD or that modifies its course in genetically confirmed or sporadic cases, clinical trial design should consider stratified designs based on the presence of an autosomal dominantly inherited mutation, and/or inclusion of genetic modifiers in the analysis as a covariate to account for variability in the course of FTD. This will allow better control for factors that vary substantially from person to person in FTD, such as age at onset or rate of disease progression.

CONCLUSION

Clinical trial research in FTD spectrum disorders is in its infancy. Individuals afflicted with these neurodegenerative disorders have numerous unmet needs. Development of new pharmacological interventions specifically designed for these individuals is essential as no effective disease-modifying treatments or evidence-based symptomatic therapies have been identified. Critical examination of previously published RCTs revealed potential explanations for their negative results as well as opportunities to improve future endeavours. We hope these recommendations, which are based on patient-centred and precision-medicine approaches, will help to steer clinical trials in FTD spectrum disorders in a productive direction.

Additional references can be found in the online supplementary material 1.

GLOSSARY

- **Frontotemporal dementia (FTD)**—refers to the clinical diagnoses of behavioural variant FTD and primary progressive aphasia (ie, semantic and non-fluent variants), which are mainly based on clinical manifestations and, sometimes, supported by the presence of characteristic cerebral hypometabolism, hypoperfusion or atrophy on brain imaging.
- **Frontotemporal dementia spectrum**—refers to the clinical diagnoses of behavioural variant FTD and primary progressive aphasia (ie, semantic and non-fluent variants), and to corticobasal syndrome, progressive supranuclear palsy syndrome and amyotrophic lateral sclerosis.
- **Frontotemporal lobar degeneration (FTLD)**—refers to neuropathological diagnoses where brain pathological examination reveals frontal and/or temporal lobe atrophy on macroscopy, and tau, TDP-43 or FUS immunoreactive inclusions on microscopy. For FTLD due to tau, subtypes include Pick's disease, corticobasal degeneration, progressive supranuclear palsy, FTDP-17, globular glial tauopathy and argyrophilic grain disease.
- **Patient-centred outcome**—refers to outcomes that are meaningful to patients, such as quality of life and autonomy.
- **Precision-medicine**—refers to interventions individually tailored on the basis of a patient's environmental exposure, lifestyle factors, genes, proteins, proteomics and imaging.

Author affiliations

¹Cognitive & Movement Disorders Clinic, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

²LC Campbell Cognitive Neurology Research Unit, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

³Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada

⁴Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

⁵Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK

⁶Division of Geriatric Medicine, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada

⁷Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

⁸Rotman Research Institute, Baycrest Centre for Geriatric Care, Toronto, Ontario, Canada

⁹Department of Psychology, University of Toronto, Toronto, Ontario, Canada

¹⁰Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada

¹¹Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA

¹²Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

¹³Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands

¹⁴Centre for Neurodegenerative Disorders, Neurology Clinic, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

¹⁵Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada

¹⁶Department of Neurosciences, University of California, San Diego, California, USA

¹⁷Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Acknowledgements PD and QDN would like to thank Fondation du Centre Hospitalier de l'Université de Montréal for supporting their postdoctoral training in cognitive neurology and epidemiology, respectively. PD would like to thank Sylvain G Bélisle for his help with the creation of the figures.

Contributors PD and MM were involved in the preparation of project conception. PD, QDN and MM were involved in the review's execution. PD created tables and figures, performed the statistical analyses, and prepared the initial draft of the paper with MM. Manuscript review and critique were performed by all authors. The final version was read and approved by all authors, with PD and MM incorporating their additional comments.

Funding This study was supported by operating grants from the Canadian Institutes of Health Research (MOP 327387), and the Weston Brain Institute to MM.

Competing interests PD and QDN have nothing to disclose. SEB and MM are supported by the Department of Medicine (Sunnybrook Health Sciences Centre and the University of Toronto), the Sunnybrook Foundation, the Hurvitz Brain Sciences Research Program and the Sunnybrook Research Institute. MM also receives support as co-lead of the Ontario Neurodegenerative Disease Research Initiative funded by the Ontario Brain Institute. SEB also receives support as the executive director of the Toronto Dementia Research Alliance. SEB does contract research for Eli Lilly, Biogen, GE Healthcare, Genentech, Novartis, Optina and Roche; received peer-reviewed funding from CIHR, CPSR, Brain Canada, ADDF, NIA, NIH, Leducq Foundation, OBI and Weston Brain Institute; and received speaker fees from Novartis and Eli Lilly. MM receives peer-reviewed research support from the Canadian Institutes of Health Research, Weston Brain Institute, Washington University, Parkinson Society Canada, Alzheimer's Drug Discovery Foundation, Brain Canada, Canadian Consortium on Neurodegeneration in Aging and Ontario Brain Institute. MM has also served as an advisor to Bioscience Medical Imaging CRO, Novartis, Ionis Pharmaceuticals, Arkuda Therapeutics and UCB; received honoraria from Novartis; received royalties from Henry Stewart Talks; received an investigator-initiated research grant from Teva; and received contract research support from Roche, Novartis and Axovant. NH is supported by the Canadian Consortium on Neurodegeneration in Aging and peer-reviewed grants from the Alzheimer Society of Canada (grant 15-17), Alzheimer's Drug Discovery Foundation (grant 20140503), Canadian Institutes of Health Research, National Institute on Aging of the National Institutes of Health (grant R01AG046543), and the Heart and Stroke Foundation (grant NA 7220), in addition to research contracts funded by Roche, Axovant and Lundbeck Canada. NH received consultation fees from Astellas, Lilly, Merck, Pfizer and Mediti. AEL has served as an advisor for AbbVie, Acorda, Biogen, Bristol-Myers Squibb, Janssen, Sun Pharma, Kallyope, Merck, Paladin and Corticobasal Degeneration Solutions; received honoraria from Sun Pharma, Medichem, Medtronic, AbbVie and Sunovion; received grants from Brain Canada, Canadian Institutes of Health Research, Corticobasal Degeneration Solutions, Edmond J Safra Philanthropic Foundation, Michael J Fox Foundation, the Ontario Brain Institute, National Parkinson Foundation, Parkinson Society Canada and W Garfield Weston Foundation; received publishing royalties from Elsevier, Saunders, Wiley-Blackwell, Johns Hopkins Press and Cambridge University Press. HHF receives peer-reviewed grant funding support from the Canadian Consortium on Neurodegeneration in Aging (CIHR 137794), National Institute on Aging (U19AG010483) (2U19AG032438-07), CIHR and Weston Brain Institute (Grant # 363926), and Brain Canada (IMPACT AD study), and other grant funding from Toyama Pharmaceutical,

Biohaven Pharmaceuticals and Probiobdrug. He has either current or past service agreements through UC San Diego with Banner Health, Roche Genentech, Arkuda Therapeutics, Samus, Samumed, Eisai, Merck and TauRx, and has received travel expenses from Axon Neurosciences, Alion Pharmaceuticals and Probiobdrug. All other authors declare no competing interests.

Patient consent Not required.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES

- Mercy L, Hodges JR, Dawson K, *et al.* Incidence of early-onset dementias in Cambridgeshire, United Kingdom. *Neurology* 2008;71:1496–9.
- Ratnavalli E, Brayne C, Dawson K, *et al.* The prevalence of frontotemporal dementia. *Neurology* 2002;58:1615–21.
- Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. *BMJ* 2013;347:f4827.
- Rogalski E, Sridhar J, Rader B, *et al.* Aphasic variant of Alzheimer disease: clinical, anatomic, and genetic features. *Neurology* 2016;87:1337–43.
- Giannini LAA, Irwin DJ, McMillan CT, *et al.* Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia. *Neurology* 2017;88:2276–84.
- Santos-Santos MA, Rabinovici GD, Iaccarino L, *et al.* Rates of amyloid imaging positivity in patients with primary progressive aphasia. *JAMA Neurol* 2018;75:342–52.
- Boxer AL, Yu JT, Golbe LI, *et al.* Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. *Lancet Neurol* 2017;16:552–63.
- Mahapatra RK, Edwards MJ, Schott JM, *et al.* Corticobasal degeneration. *Lancet Neurol* 2004;3:736–43.
- Burrell JR, Halliday GM, Kril JJ, *et al.* The frontotemporal dementia-motor neuron disease continuum. *Lancet* 2016;388:919–31.
- Phukan J, Elamin M, Bede P, *et al.* The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. *J Neurol Neurosurg Psychiatry* 2012;83:102–8.
- Cairns NJ, Bigio EH, Mackenzie IR, *et al.* Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. *Acta Neuropathol* 2007;114:5–22.
- Neumann M, Rademakers R, Roeber S, *et al.* A new subtype of frontotemporal lobar degeneration with FUS pathology. *Brain* 2009;132(Pt 11):2922–31.
- Mackenzie IR, Baborie A, Pickering-Brown S, *et al.* Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. *Acta Neuropathol* 2006;112:539–49.
- Seelaar H, Rohrer JD, Pijnenburg YA, *et al.* Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg Psychiatry* 2011;82:476–86.
- Masellis M, Momeni P, Meschino W, *et al.* Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. *Brain* 2006;129(Pt 11):3115–23.
- Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. *J Clin Invest* 2005;115:1449–57.
- Yokoyama JS, Karch CM, Fan CC, *et al.* Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. *Acta Neuropathol* 2017;133:825–37.
- Synofzik M, Born C, Rominger A, *et al.* Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. *Neurobiol Aging* 2014;35:1212.e1–5.
- Yan J, Deng HX, Siddique N, *et al.* Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. *Neurology* 2010;75:807–14.
- Ferrari R, Wang Y, Vandrovicova J, *et al.* Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. *J Neurol Neurosurg Psychiatry* 2017;88:152–64.
- Zhao Y, Tseng IC, Heyser CJ, *et al.* Apoptosis-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. *Neuron* 2015;87:963–75.
- Höglinger GU, Melhem NM, Dickson DW, *et al.* Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet* 2011;43:699–705.
- Van Deerlin VM, Sleiman PM, Martinez-Lage M, *et al.* Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nat Genet* 2010;42:234–9.
- Cruchaga C, Graff C, Chiang HH, *et al.* Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. *Arch Neurol* 2011;68:581–6.
- Pottier C, Zhou X, Perkerson RB, *et al.* Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurol* 2018;17:548–58.
- van Blitterswijk M, Mullen B, Nicholson AM, *et al.* TMEM106B protects C9orf72 expansion carriers against frontotemporal dementia. *Acta Neuropathol* 2014;127:397–406.

- 27 Gallagher MD, Suh E, Grossman M, *et al.* TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. *Acta Neuropathol* 2014;127:407–18.
- 28 Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. *J Neurochem* 2016;138(Suppl 1):211–21.
- 29 Armstrong MJ, Litvan I, Lang AE, *et al.* Criteria for the diagnosis of corticobasal degeneration. *Neurology* 2013;80:496–503.
- 30 Rasovsky K, Hodges JR, Knopman D, *et al.* Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134(Pt 9):2456–77.
- 31 Gorno-Tempini ML, Hillis AE, Weintraub S, *et al.* Classification of primary progressive aphasia and its variants. *Neurology* 2011;76:1006–14.
- 32 Höglinger GU, Respondek G, Stamelou M, *et al.* Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. *Mov Disord* 2017;32:853–64.
- 33 Mendez MF, Shapira JS, McMurtry A, *et al.* Accuracy of the clinical evaluation for frontotemporal dementia. *Arch Neurol* 2007;64:830–5.
- 34 Liberati A, Altman DG, Tetzlaff J, *et al.* The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.
- 35 Mitumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? *Lancet Neurol* 2014;13:1127–38.
- 36 Higgins JP, Altman DG, Gøtzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- 37 IBM CR. *IBM SPSS Statistics for windows, version 24.0.* Armonk, NY: IBM Corp, 2016.
- 38 Leclair-Visonneau L, Rouaud T, Debilly B, *et al.* Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. *Clin Neurol Neurosurg* 2016;146:35–9.
- 39 Nuebling G, Hensler M, Paul S, *et al.* PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. *J Neurol* 2016;263:1565–74.
- 40 Apetauerova D, Scala SA, Hamill RW, *et al.* CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. *Neurol Neuroimmunol Neuroinflamm* 2016;3:e266.
- 41 Pardini M, Serrati C, Guida S, *et al.* Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. *Neurodegener Dis* 2015;15:58–62.
- 42 Hughes LE, Rittman T, Regenthal R, *et al.* Improving response inhibition systems in frontotemporal dementia with citalopram. *Brain* 2015;138(Pt 7):1961–75.
- 43 Finger EC, MacKinley J, Blair M, *et al.* Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. *Neurology* 2015;84:174–81.
- 44 Tolosa E, Litvan I, Höglinger GU, *et al.* A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. *Mov Disord* 2014;29:470–8.
- 45 Höglinger GU, Huppertz HJ, Wagenpfeil S, *et al.* Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. *Mov Disord* 2014;29:479–87.
- 46 Boxer AL, Lang AE, Grossman M, *et al.* Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. *Lancet Neurol* 2014;13:676–85.
- 47 Boxer AL, Knopman DS, Kaufer DI, *et al.* Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2013;12:149–56.
- 48 Jesso S, Morlog D, Ross S, *et al.* The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. *Brain* 2011;134(Pt 9):2493–501.
- 49 Vercelletto M, Boutoleau-Bretonnière C, Volteau C, *et al.* Memantine in behavioral variant frontotemporal dementia: negative results. *J Alzheimers Dis* 2011;23:749–59.
- 50 Bensimon G, Ludolph A, Agid Y, *et al.* Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. *Brain* 2009;132(Pt 1):156–71.
- 51 Stamelou M, Reuss A, Pilatus U, *et al.* Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. *Mov Disord* 2008;23:942–9.
- 52 Kertesz A, Morlog D, Light M, *et al.* Galantamine in frontotemporal dementia and primary progressive aphasia. *Dement Geriatr Cogn Disord* 2008;25:178–85.
- 53 Rahman S, Robbins TW, Hodges JR, *et al.* Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. *Neuropsychopharmacology* 2006;31:651–8.
- 54 Deakin JB, Rahman S, Nestor PJ, *et al.* Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. *Psychopharmacology* 2004;172:400–8.
- 55 Moretti R, Torre P, Antonello RM, *et al.* Rivastigmine in frontotemporal dementia: an open-label study. *Drugs Aging* 2004;21:931–7.
- 56 Lebert F, Stekke W, Hasenbroekx C, *et al.* Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord* 2004;17:355–9.
- 57 Moretti R, Torre P, Antonello RM, *et al.* Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. *Eur Neurol* 2003;49:13–19.
- 58 Litvan I, Phipps M, Pharr VL, *et al.* Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. *Neurology* 2001;57:467–73.
- 59 Frattali CM, Sonies BC, Chi-Fishman G, *et al.* Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. *Dysphagia* 1999;14:165–8.
- 60 Rascol O, Sieradzan K, Peyro-Saint-Paul H, *et al.* Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. *Mov Disord* 1998;13:673–6.